You are here:Home-Chemical Inhibitors & Agonists-JAK/STAT Signaling-JAK-PF-06700841 tosylate
PF-06700841 tosylate

Chemical Structure : PF-06700841 tosylate

CAS No.: 2140301-96-6

PF-06700841 tosylate (Brepocitinib tosylate, PF-6700841, PF-841)

Catalog No.: PC-61818Not For Human Use, Lab Use Only.

PF-06700841 tosylate (Brepocitinib, PF 06700841) is a potent dual JAK1/TYK2 inhibitor with IC50 of 17/23 nM, inhibits JAK2 and JAK3 with IC50=77 and 6494 nM, respectively.

Packing Price Stock Quantity
10 mg $128 In stock
25 mg $218 In stock
50 mg $368 In stock
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

PF-06700841 tosylate (Brepocitinib, PF 06700841) is a potent dual JAK1/TYK2 inhibitor with IC50 of 17/23 nM, inhibits JAK2 and JAK3 with IC50=77 and 6494 nM, respectively.
PF-06700841 potently inhibits TYK2/JAK2 mediated IL-12/pSTAT4 and IL-23/pSTAT3 (HWB IC50=65 and 120 nM, respectively).
PF-06700841 has good potency against IL6/pStat1 in the CD3+ cellular subset (IC50 = 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3+ cellular subset (IC50=641 nM).
PF-06700841 inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34+ progenitor cells (IC50=577 nM).
IL10/pSTAT3 (TYK2/JAK1) and IL27/pSTAT3 (JAK1/JAK2/TYK2) are also inhibited by PF-06700841 with IC50=305 nM and 86 nM, respectively.
PF-06700841 shows good selectivity against a broad panel of receptors with exception for kinase insert domain receptor (KDR) (VEGFR2) (IC50=1600 nM); shows therapeutic eggect in the rat adjuvant induced arthritis (AIA) following oral dosing.

Physicochemical Properties

M.Wt 561.609
Formula C25H29F2N7O4S
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone 4-methylbenzenesulfonate

References

1. Banfield C, et al. J Clin Pharmacol. 2017 Dec 21. doi: 10.1002/jcph.1046.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: